Nurix Therapeutics (NRIX) Osake Kurssi

Nurix Therapeutics Inc primarily operates in the biotechnology and pharmaceutical industries.

The main competitors of Nurix Therapeutics Inc in the market include other biotechnology companies such as Vertex Pharmaceuticals, Inc., Gilead Sciences, Inc., and Amgen Inc.

Nurix Therapeutics Inc is a biopharmaceutical company specializing in targeted protein modulation to develop novel therapies for diseases with unmet medical needs. Founded in 2015, the company focuses on utilizing its proprietary protein degradation platform to discover and develop small molecule drugs that selectively degrade disease-causing proteins. Nurix Therapeutics aims to address various indications, including oncology, immunology, and neurodegenerative disorders. With its innovative technology and strategic partnerships, the company has made significant progress in advancing its pipeline and has emerged as a leader in the protein degradation field. Nurix Therapeutics is committed to delivering transformative treatments to improve patient outcomes.

Nurix Therapeutics Inc has achieved several significant milestones. The company successfully raised $120 million in a Series B funding round, strengthening its financial position to advance its drug discovery and development programs. Nurix also entered into a strategic collaboration with Gilead Sciences, a renowned pharmaceutical company, to discover and develop innovative therapies for various diseases. Additionally, Nurix entered into multiple partnerships with global biopharmaceutical companies, including Sanofi and Vertex, to leverage its proprietary protein modulation platform. These collaborations validate Nurix's expertise and highlight its potential in developing novel therapies for patients in need.

Nurix Therapeutics Inc is primarily present in the United States.

Nurix Therapeutics Inc represents values of innovation, collaboration, and dedication to advancing therapies for patients. With a mission to discover and develop targeted protein modulation drugs, the company utilizes its innovative drug discovery platform to identify and modify specific proteins that play crucial roles in disease pathways. By fostering strong collaborations with leading academic institutions and industry partners, Nurix Therapeutics Inc aims to accelerate the development of breakthrough treatments. Committed to improving patients' lives, the company's corporate philosophy revolves around scientific excellence, integrity, and a patient-centric approach. Through its cutting-edge research and dedication to transformative therapies, Nurix Therapeutics Inc stands as a leader in the field.

Analyytikot asettavat tällä hetkellä Nurix Therapeutics-osakkeelle keskimääräisen tavoitehinnan 34,67 USD (mediaani: 34,00 USD), mikä merkitsee +56,1 % viimeisimpään hintaan verrattuna. Konsensus perustuu 21 analyytikkoarvioon.

Nurix Therapeutics Analyytikkojen kursstavoitteet 2026

21 analyytikkoa arvioi tällä hetkellä Nurix Therapeutics-osaketta: 19 suosittaa ostoa, 2 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Nurix Therapeutics-yhtiöltä 68,45 M USD liikevaihtoa ja −2,92 USD osakekohtaista tulosta.

Nurix Therapeutics Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Nurix Therapeutics-osake noteerataan hintaan 19,82 EUR (22,21 USD).

Nurix Therapeutics-osake (NRIX) on listattuna 1 pörssissä, muun muassa: NASDAQ (NRIX).

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics that selectively modulate E3 ubiquitin ligases to treat diseases. The company's business model is based on utilizing its proprietary protein regulation technology platform, the DNA-Encoded Libraries (DEL) system. This innovative platform allows for the simultaneous testing and analysis of thousands of molecules to identify potential therapeutic candidates that specifically interact with E3 ligases. This technology also enables efficient optimization of drug compounds and facilitates the rapid identification of candidates capable of specifically regulating protein stability and activity within cells. Nurix Therapeutics has been committed to the discovery and development of therapeutics based on the modulation of E3 ubiquitin ligases since its founding in 2013. The company offers a wide range of products focused on target identification and drug candidate development. Its team of experts in chemistry, biology, bioinformatics, and medicine has expertise in researching therapeutics underlying the regulatory mechanisms of E3 ligases within cells. The main goal of Nurix Therapeutics is to leverage the fundamental research of E3 ligase systems and develop innovative therapeutic solutions for diseases such as cancer, inflammation, and metabolic disorders. E3 ligases play a crucial role in controlling protein stability and activity, and dysregulation of this system can trigger severe diseases and disorders. At its core, Nurix Therapeutics utilizes its technology platform to specifically identify the E3 ligases involved in various diseases. The company aims to develop targeted molecular medicines that regulate these specific E3 ligases, thereby providing therapeutic benefits. This business model allows the company to optimize both risks and returns by developing and maintaining a specific pipeline of therapeutics. Nurix Therapeutics secured funding through venture capital in 2015 during its early stages. Since then, the company has established partnerships with major pharmaceutical companies and entered into research agreements with academic institutions and leading hospitals in North America and Europe. These partnerships have allowed the company to expand both its technical expertise and its access to relevant research areas. Overall, Nurix Therapeutics has built a collaborative model where partnerships contribute to the advancement in the development and commercialization of therapeutics. The company has a strong pipeline with a range of candidates for drug development expected to be brought to market in the coming years. The business model of Nurix Therapeutics is based on its technology platform, which allows for the targeted regulation of E3 ligases involved in various diseases and disorders. By developing specialized molecular medicines, the company hopes to create therapeutic benefits for patients suffering from a range of conditions. With a series of partnerships and a strong pipeline, Nurix Therapeutics is in a good position to continue developing and advancing innovative solutions for disease treatment.

odotettu liikevaihto Nurix Therapeutics on 68,45 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Nurix Therapeutics on −277,26 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Nurix Therapeutics:n hinta-voitto-suhde (P/E) on tällä hetkellä −7,62. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Nurix Therapeutics-osakkeen arvostusta.

Nurix Therapeutics:n hinta-myynti-suhde (P/S) on tällä hetkellä 30,85. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Nurix Therapeutics-osakkeen arvostuskennuslukuna.

Nurix Therapeutics:n Eulpool-laatuscore on 3/10.

Nurix Therapeutics:n ISIN on US67080M1036. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Nurix Therapeutics:n WKN on A2P85Z. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Nurix Therapeutics:n ticker on NRIX. Tämä pörssinoteeraus käytetään Nurix Therapeutics-osakkeiden kauppaan pörssissä.